Macrogenics (MGNX) Return on Capital Employed (2013 - 2026)
Macrogenics' (MGNX) quarterly Return on Capital Employed came in at 45.01% in Q1 2026, up 798.0% year-on-year from 5.01% in Q1 2025, and down 36.38% on a QoQ basis from 33.01% in Q4 2025.
Macrogenics (MGNX) Return on Capital Employed (2013 - 2026) Analysis & Trends
Macrogenics (MGNX) has 14 years of Return on Capital Employed data on file, last reported at 45.01% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 798.0% year-over-year to 45.01% in Q1 2026; TTM through Mar 2026 was 45.01%, a 798.0% increase from a year earlier, with the FY2025 full-year figure at 33.7%, up 1555.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 45.01%, down from 33.01% in the prior quarter.
- Over the last five years, Return on Capital Employed for MGNX reached as high as 33.01% in Q4 2025 and fell as low as 122.34% in Q3 2022.
- Historically, Return on Capital Employed has averaged 65.07% across 5 years, with a median of 53.28% in 2024.
- Across the five-year window, Return on Capital Employed surged 8296 bps in 2023 and plunged 8349 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 64.14% in 2022, then climbed by 0 bps to 63.95% in 2023, then gained by 17 bps to 53.28% in 2024, then jumped by 38 bps to 33.01% in 2025, then sank by 36 bps to 45.01% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 45.01% in Q1 2026, 33.01% in Q4 2025, and 53.17% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Macrogenics | 254.43 Mn | 187.92 Mn | - | -45.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.01% |
| Dec 31, 2025 | -33.01% |
| Sep 30, 2025 | -53.17% |
| Jun 30, 2025 | -39.81% |
| Mar 31, 2025 | -52.99% |
| Dec 31, 2024 | -53.28% |
| Sep 30, 2024 | -61.72% |
| Jun 30, 2024 | -117.97% |
| Mar 31, 2024 | -84.37% |
| Dec 31, 2023 | -63.95% |
| Sep 30, 2023 | -39.37% |
| Jun 30, 2023 | -34.49% |
| Mar 31, 2023 | -34.99% |
| Dec 31, 2022 | -64.14% |
| Sep 30, 2022 | -122.34% |
| Jun 30, 2022 | -113.31% |
| Mar 31, 2022 | -92.34% |
| Dec 31, 2021 | -70.14% |
| Sep 30, 2021 | -43.13% |
| Jun 30, 2021 | -36.00% |